ECSP088647A - Nueva sal de citrato de un derivado de indol y su uso farmacéutico - Google Patents
Nueva sal de citrato de un derivado de indol y su uso farmacéuticoInfo
- Publication number
- ECSP088647A ECSP088647A EC2008008647A ECSP088647A ECSP088647A EC SP088647 A ECSP088647 A EC SP088647A EC 2008008647 A EC2008008647 A EC 2008008647A EC SP088647 A ECSP088647 A EC SP088647A EC SP088647 A ECSP088647 A EC SP088647A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical use
- citrate salt
- salt
- indol derivative
- new
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000001860 citric acid derivatives Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- QIXMKFAORYGAFN-UHFFFAOYSA-N 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile 2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.Oc1[nH]c2ccc(cc2c1-c1ccc(CN2CCOCC2)cn1)C#N QIXMKFAORYGAFN-UHFFFAOYSA-N 0.000 abstract 1
- 102000001267 GSK3 Human genes 0.000 abstract 1
- 108060006662 GSK3 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76455106P | 2006-02-02 | 2006-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088647A true ECSP088647A (es) | 2008-08-29 |
Family
ID=38327680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008647A ECSP088647A (es) | 2006-02-02 | 2008-07-24 | Nueva sal de citrato de un derivado de indol y su uso farmacéutico |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8008294B2 (OSRAM) |
| EP (1) | EP1981869A4 (OSRAM) |
| JP (1) | JP2009525324A (OSRAM) |
| KR (1) | KR20080098022A (OSRAM) |
| CN (2) | CN101379053A (OSRAM) |
| AR (1) | AR059225A1 (OSRAM) |
| AU (1) | AU2007210336B2 (OSRAM) |
| BR (1) | BRPI0706745A2 (OSRAM) |
| CA (1) | CA2641900A1 (OSRAM) |
| EC (1) | ECSP088647A (OSRAM) |
| IL (1) | IL192888A0 (OSRAM) |
| MX (1) | MX2008009719A (OSRAM) |
| MY (1) | MY146102A (OSRAM) |
| NO (1) | NO20083784L (OSRAM) |
| NZ (1) | NZ570849A (OSRAM) |
| PE (1) | PE20090192A1 (OSRAM) |
| RU (1) | RU2415137C2 (OSRAM) |
| SA (1) | SA07280004B1 (OSRAM) |
| SG (1) | SG169381A1 (OSRAM) |
| TW (1) | TW200800977A (OSRAM) |
| UA (1) | UA94251C2 (OSRAM) |
| UY (1) | UY30126A1 (OSRAM) |
| WO (1) | WO2007089191A1 (OSRAM) |
| ZA (1) | ZA200806725B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| WO2008130312A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| US20100267720A1 (en) * | 2007-07-30 | 2010-10-21 | Astrazeneca Ab | Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate |
| US20100189788A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439593C (en) | 2001-04-05 | 2010-02-09 | Torrent Pharmaceuticals Ltd. | Heterocyclic compounds for aging-related and diabetic vascular complications |
| JP2003009588A (ja) | 2001-06-20 | 2003-01-10 | Toshiba Corp | 車両連続運転装置用インバータ装置 |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| US20050054663A1 (en) * | 2003-08-13 | 2005-03-10 | Bennett Christina N. | GSK-3 inhibitors |
| TWI427077B (zh) | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
| SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
-
2007
- 2007-01-23 SA SA07280004A patent/SA07280004B1/ar unknown
- 2007-01-29 TW TW096103245A patent/TW200800977A/zh unknown
- 2007-01-29 AR ARP070100366A patent/AR059225A1/es not_active Application Discontinuation
- 2007-01-31 EP EP07709302A patent/EP1981869A4/en not_active Withdrawn
- 2007-01-31 CN CNA2007800041531A patent/CN101379053A/zh active Pending
- 2007-01-31 NZ NZ570849A patent/NZ570849A/en not_active IP Right Cessation
- 2007-01-31 MX MX2008009719A patent/MX2008009719A/es active IP Right Grant
- 2007-01-31 KR KR1020087019047A patent/KR20080098022A/ko not_active Ceased
- 2007-01-31 CN CNA2007800043630A patent/CN101378754A/zh active Pending
- 2007-01-31 BR BRPI0706745-3A patent/BRPI0706745A2/pt not_active IP Right Cessation
- 2007-01-31 JP JP2008553201A patent/JP2009525324A/ja not_active Ceased
- 2007-01-31 WO PCT/SE2007/000086 patent/WO2007089191A1/en not_active Ceased
- 2007-01-31 AU AU2007210336A patent/AU2007210336B2/en not_active Ceased
- 2007-01-31 SG SG201100793-7A patent/SG169381A1/en unknown
- 2007-01-31 RU RU2008131906/04A patent/RU2415137C2/ru not_active IP Right Cessation
- 2007-01-31 CA CA002641900A patent/CA2641900A1/en not_active Abandoned
- 2007-01-31 US US12/162,540 patent/US8008294B2/en not_active Expired - Fee Related
- 2007-01-31 UY UY30126A patent/UY30126A1/es not_active Application Discontinuation
- 2007-01-31 UA UAA200809265A patent/UA94251C2/ru unknown
- 2007-01-31 MY MYPI20082900A patent/MY146102A/en unknown
- 2007-02-02 US US11/670,681 patent/US20070203137A1/en not_active Abandoned
- 2007-08-02 PE PE2007001013A patent/PE20090192A1/es not_active Application Discontinuation
-
2008
- 2008-07-17 IL IL192888A patent/IL192888A0/en unknown
- 2008-07-24 EC EC2008008647A patent/ECSP088647A/es unknown
- 2008-08-01 ZA ZA200806725A patent/ZA200806725B/xx unknown
- 2008-09-02 NO NO20083784A patent/NO20083784L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101378754A (zh) | 2009-03-04 |
| US20070203137A1 (en) | 2007-08-30 |
| MY146102A (en) | 2012-06-29 |
| IL192888A0 (en) | 2009-02-11 |
| NO20083784L (no) | 2008-10-13 |
| AU2007210336B2 (en) | 2011-03-24 |
| RU2415137C2 (ru) | 2011-03-27 |
| KR20080098022A (ko) | 2008-11-06 |
| CN101379053A (zh) | 2009-03-04 |
| ZA200806725B (en) | 2009-07-29 |
| US20090023732A1 (en) | 2009-01-22 |
| NZ570849A (en) | 2011-01-28 |
| AU2007210336A1 (en) | 2007-08-09 |
| AR059225A1 (es) | 2008-03-19 |
| SG169381A1 (en) | 2011-03-30 |
| JP2009525324A (ja) | 2009-07-09 |
| SA07280004B1 (ar) | 2011-10-29 |
| UY30126A1 (es) | 2007-09-28 |
| UA94251C2 (ru) | 2011-04-26 |
| RU2008131906A (ru) | 2010-03-10 |
| TW200800977A (en) | 2008-01-01 |
| CA2641900A1 (en) | 2007-08-09 |
| BRPI0706745A2 (pt) | 2011-04-05 |
| EP1981869A1 (en) | 2008-10-22 |
| MX2008009719A (es) | 2008-09-04 |
| US8008294B2 (en) | 2011-08-30 |
| EP1981869A4 (en) | 2010-08-25 |
| PE20090192A1 (es) | 2009-03-20 |
| WO2007089191A1 (en) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| AR064220A1 (es) | Formulacion liofilizada mab abeta | |
| EA201001577A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| DOP2011000203A (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| ECSP088647A (es) | Nueva sal de citrato de un derivado de indol y su uso farmacéutico | |
| ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| UY32190A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales | |
| CL2007002919A1 (es) | Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades. | |
| DOP2010000197A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| AR062784A1 (es) | Tratmiento de los vertigos con acetil -l- leucina | |
| ECSP088988A (es) | Derivados de ácido fenilacético | |
| WO2007100282A8 (en) | New salts of an indole derivative and their use in medicine | |
| CL2009000551A1 (es) | Uso de 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol, o una sal farmaceuticamente aceptable del mismo, para tratar un trastorno relacionado con los ojos como la degeneracion macular, retinopatia diabetica o edema macular diabetico y composicion farmaceutica que comprende a dicho compuesto. | |
| AR061741A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CL2007002918A1 (es) | Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades. |